Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 16c, Misses on Revenue; Offers FY24 Revenue Guidance

Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q1 EPS of $0.38, $0.16 better than the analyst estimate of $0.22. Revenue for the quarter came in at $98.44 million versus the consensus estimate of $99.03 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2024 revenue of $455-475 million, versus the consensus of $460.5 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance